HPV vaccine effectiveness against cervical cancer (VIDEO)

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.